Summit Global Diversifies Investments
Summit Global Investments Acquires New Stakes in Five Companies, Expanding Diverse Portfolio
Key Points
National HealthCare’s investor landscape is already highly active beyond Summit’s new stake, with major institutions such as Morgan Stanley Institutional Investment Advisors, First Trust Advisors, Geode Capital Management, Goldman Sachs, and Arrowstreet Capital holding sizable positions; overall institutional ownership of NHC is about 56.44%.
Avista has a very high level of institutional ownership (about 85.24%), with key holders including Royal Bank of Canada (65,494 shares), AQR Capital Management (69,831 shares), and UBS AM (283,182 shares), among others.
TTM Technologies shows notable insider activity in addition to Summit’s new stake: Executive Vice President Shawn A. Powers sold 9,856 shares (~$2.07 million) on June 23, and EVP Catherine A. Gridley sold 8,966 shares (~$1.88 million) on the same day, reflecting ongoing insider portfolio management.
FormFactor also saw insider selling by two directors: Brian C. White sold 3,250 shares (~$409,500) on May 20, and Dennis Thomas St sold 2,800 shares on June 15 (around $424,000), illustrating routine governance activity alongside institutional buying.
McKesson’s stock fundamentals in the period include an opening price of $868.72, a 50-day moving average of $813.45, a 200-day moving average of $842.81, a market cap near $101.28 billion, a P/E of 23.25, a PEG of 1.68, and a beta of 0.30; the company also announced an upcoming quarterly dividend payable on October 1 to shareholders of record September 1.
Summit Global Investments quietly built a diversified portfolio footprint in the second quarter, disclosing new stakes in five companies spanning healthcare, utilities, technology, semiconductors, and drug distribution, according to Ticker Report and Watchlist News. The firm's largest new bet was on Avista, a utility company, where it picked up 32,535 shares worth roughly $1.33 million.
Across the five positions, Summit deployed an estimated $5.15 million. The moves signal a broad, sector-spanning strategy rather than a concentrated bet on any single industry.
Five New Stakes Spread Across Five Sectors
Summit's five new positions cover a wide range of industries. It bought 4,298 shares of National HealthCare for about $908,000. It added 32,535 shares of Avista for roughly $1.33 million. It picked up 4,193 shares of TTM Technologies for around $784,000. It also grabbed 6,063 shares of FormFactor for about $970,000 and 1,533 shares of McKesson for approximately $1.16 million, according to Watchlist News.
The purchases reflect a classic diversification play. Healthcare, utilities, tech hardware, semiconductors, and wholesale drug distribution each carry different risk profiles. Spreading across all five suggests Summit is hedging rather than making a single directional call on any one market.
Big Institutions Already Dominate These Stocks
Summit is far from alone in these names. Avista already has institutional ownership of about 85.24%. Key holders there include UBS AM with 283,182 shares, AQR Capital Management with 69,831 shares, and Royal Bank of Canada with 65,494 shares, per Watchlist News. National HealthCare sits at about 56.44% institutional ownership, with major names like Morgan Stanley, Goldman Sachs, and Geode Capital Management already holding sizable positions.
High institutional ownership can cut both ways. It signals that large, well-resourced funds see value in a stock. But it also means less room for new buyers to move the price. Summit is stepping into crowded trades in at least two of its five new picks.
Insiders Were Selling at TTM and FormFactor
While Summit was buying into TTM Technologies and FormFactor, insiders at both companies were selling. At TTM, Executive Vice President Shawn A. Powers sold 9,856 shares for about $2.07 million on June 23. On the same day, EVP Catherine A. Gridley sold 8,966 shares for roughly $1.88 million, according to Watchlist News.
FormFactor saw similar activity. Director Brian C. White sold 3,250 shares for about $409,500 on May 20. Director Dennis Thomas St sold 2,800 shares for around $424,000 on June 15. Insider selling does not always signal trouble — executives often sell shares for personal financial reasons — but the timing is worth noting alongside Summit's fresh buying.
McKesson's Steady Fundamentals Round Out the Portfolio
McKesson stands out as the most fundamentally stable of Summit's five picks. The stock opened the period at $868.72. Its 50-day moving average sits at $813.45 and its 200-day moving average at $842.81. The company carries a market cap near $101.28 billion, a price-to-earnings ratio of 23.25, and a low beta of 0.30 — meaning it moves far less than the broader market, per Watchlist News.
McKesson also announced a quarterly dividend payable on October 1 to shareholders of record as of September 1. That dividend adds an income component to the position. For a firm like Summit building a diversified book, a low-volatility, dividend-paying giant like McKesson offers ballast alongside higher-risk tech and semiconductor names.
Sentiment
Mostly PositivePublishers
47
Articles
33
Reach
80
